Drug Database
TJ

TJ-23 (TSS)

✓ Approved

Tsumura · ESR1

什么是 TJ-23?

TJ-23 是一种治疗药物,由Tsumura研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名TSS
公司Tsumura
分子靶点ESR1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

TJ-23 作用于 1 个分子靶点:

ESR1estrogen receptor 1 (ER, ESR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

TJ-23 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Reproductive system and breast disordersInfertility female✓ Approved

相关研究文献

PubMedJournal of animal science2026-11-17

Comparing the effects of rumen and E. coli lipopolysaccharides on barrier function and immunogenicity using an in vitro inflammation model.

Yu Yaling Y, Wang Tao T, Azevedo Paula P, Jiang Yixin Y et al.

Subacute ruminal acidosis (SARA) is a prevalent metabolic disorder in high-yielding dairy cows, characterized by luminal accumulation of lipopolysaccharides (LPS). However, the effects of LPS source on epithelial barrier integrity and inflammatory responses remain poorly defined. This study compared rumen-derived and Escherichia coli LPS (E. coli LPS, E-LPS) using bovine ruminal epithelial cells (RECs) and porcine intestinal epithelial cells (IPEC-J2 cells). LPS-induced cytotoxicity, barrier permeability, and the expression of tight-junction (TJ) proteins and cytokines were evaluated. Evaluation of LPS dose effects indicated that at 25-75 × 10³ EU/mL, E-LPS induced inflammatory responses without notable cytotoxicity, while at 200 × 10³ EU/mL it significantly compromised cell viability and barrier integrity. Rumen LPS (R-LPS) was isolated from cows fed a high-concentrate diet and verified to be structurally distinct from E-LPS. Both LPS types decreased cell viability in a dose-dependent manner, with R-LPS exerting a stronger effect, especially in IPEC-J2 cells (P < 0.05). In IPEC-J2 cells, R-LPS significantly reduced transepithelial electrical resistance (TEER; decrease to 90-47%, P < 0.001), while E-LPS had little effect. Conversely, E-LPS induced a greater increase in FITC-dextran permeability (+110%). Both LPS types upregulated TJ-related genes expression, but R-LPS suppressed TJ protein expression more strongly in RECs, while E-LPS modestly increased these proteins in IPEC-J2 cells (P > 0.05). Cytokine gene expression increased in a dose-dependent manner. R-LPS induced stronger IL-1β, IL-6, and IL-8 responses (P < 0.05), particularly in RECs, whereas E-LPS preferentially upregulated TNF-α (P < 0.05). Both LPS types elevated IL-10, with R-LPS inducing higher expression in IPEC-J2 cells (P > 0.05). These findings demonstrate that rumen-derived LPS exerts a stronger disruptive effect on TJ function by interleukins, and E-LPS shows greater immunogenicity by TNF-α, highlighting the distinct immunogenicity of LPS sources and the increased sensitivity of the RECs.

PMID 43040637
阅读全文 →
PubMedFrontiers in surgery2026-11-17

Early (<3 months) versus late (≥3 months) periprosthetic femoral fractures after hip arthroplasty: fracture characteristics and treatment patterns.

Qiu Changmao C, Zhang Kai K, Wang Qikui Q, Zhang Ruipeng R et al.

To describe and compare injury context, fracture morphology, bone stock, and treatment patterns between periprosthetic femoral fractures (PFFs) occurring <3 months and ≥3 months after index hip arthroplasty using a prespecified operational timing threshold. We retrospectively reviewed consecutive patients hospitalized for their first documented PFF episode after total hip arthroplasty or hemiarthroplasty at a tertiary orthopedic referral hospital from January 2021 through December 2025. Early PFF was defined as <3 months and late PFF as ≥3 months using a prespecified primary operational cutoff based on the month-level interval from index arthroplasty to PFF. Between-group comparisons used Wilcoxon rank-sum tests, Fisher exact tests, and standardized mean differences (SMDs). P values were interpreted descriptively, and absolute percentage-point differences with 95% confidence intervals (CIs) were reported for selected binary contrasts. A 6-month cutoff was examined post hoc as a sensitivity analysis. Among 132 patients, 126 had a usable month-based interval; 23 (18.3%) had early PFF and 103 (81.7%) had late PFF. Low-energy injury was recorded in 23/23 (100.0%) early PFFs and 86/102 (84.3%) late PFFs, corresponding to an absolute difference of 15.7 percentage points (95% CI, 0.2-24.0). Vancouver B2/B3 fractures occurred in 8/23 (34.8%) versus 22/102 (21.6%) patients (absolute difference, 13.2 percentage points; 95% CI, -5.1-34.7). Surgery was performed in 21/23 (91.3%) versus 88/103 (85.4%), and ORIF was the most frequent treatment in both groups. At the 6-month cutoff, multiple fracture categories and treatment strategies remained represented in both timing groups. In this cohort, a 3-month operational grouping suggested a difference in recorded injury context, while both timing groups included multiple fracture morphologies, bone-stock categories, and treatment strategies. Timing may provide useful contextual information at presentation but should be interpreted together with Vancouver classification, implant stability, bone stock, and patient condition. These observations require validation in larger cohorts with finer timing resolution.

PMID 43041422
阅读全文 →
PubMedPediatric blood & cancer2026-11-17

Trametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibroma-Real-World Data From the SACHA-France Study.

Vanderkelen Clara Rigaud CR, Aerts Isabelle I, Sevrin François F, Ndounga-Diakou Lee Aymar LA et al.

Neurofibromatosis type 1 (NF-1) frequently leads to inoperable, symptomatic plexiform neurofibromas (PNs) with limited therapeutic options. This study evaluates the real-world activity and safety of the MEK inhibitor trametinib in pediatric NF-1 patients with inoperable PNs in France. We analyzed pediatric patients enrolled in the SACHA-France study (NCT04477681) who received trametinib for inoperable PNs between 01/2020 and 01/2026. Antitumor activity was evaluated by treating physicians using response evaluation criteria in solid tumors (RECIST) 1.1 criteria. Adverse events (AEs) were graded per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Clinical benefit data were collected retrospectively. Twenty-three patients (median age: 6 years [range: 0-17]) were included. Clinical benefit occurred in 87% (20/23), mainly through pain reduction (86% of symptomatic patients, 12/14). RECIST assessment showed partial response in 4% (1/23), stable disease in 87% (20/23), and progression in 9% (2/23). AEs occurred in 96% of patients, predominantly cutaneous (96%) and Grade 1-2. Four Grade 3 AEs were reported (osteitis, paronychia [n = 2], elevated creatine kinase), prompting discontinuation in 2 cases. Median treatment duration was 33 months [range: 1-58]. Treatment was discontinued in seven patients for prolonged stable disease, four for disease progression (two clinical, two radiological), two for severe AEs, and one for poor adherence. Nine patients remained on treatment at cutoff. Trametinib provided notable clinical benefit and disease stabilization in pediatric NF-1-associated PNs, despite limited RECIST-defined tumor shrinkage. The safety profile was manageable and consistent with known data. Comparative studies with other MEK inhibitors are warranted to optimize treatment strategies.

PMID 43042859
阅读全文 →
PubMedCrohn's & colitis 3602026-11-17

Dose escalation of IL-23 inhibitors in inflammatory bowel disease: a systematic review of efficacy and safety.

Coman Diana D, Farkouh Amar A, Dufresne Alice A, Bernard Edmond-Jean EJ et al.

IL-23 antagonists have proven effective for induction and maintenance of remission in inflammatory bowel disease (IBD). However, suboptimal response and secondary loss of response are common, and evidence supporting dose-escalation strategies remains limited. We aimed to systematically evaluate the efficacy and safety of IL-23 inhibitor dose escalation in IBD. We conducted a systematic review of studies reporting dose escalation of Risankizumab, Mirikizumab, or Guselkumab in adult patients with Crohn's disease (CD) or ulcerative colitis (UC). MEDLINE, Embase, and Web of Science were searched from inception to November 2025. Dose escalation was defined as interval shortening, dose increase, or intravenous re-induction. Primary outcomes were clinical remission, steroid-free remission, and endoscopic remission. Secondary outcomes included clinical response and endoscopic response, biomarker improvement, and safety. Twelve studies met inclusion criteria, including 1694 patients treated with an IL-23 antagonist. Among them, 578 (34.1%) underwent dose escalation. The total study population included 61% UC and 39% CD patients. Among patients undergoing dose escalation, 65.7% had UC. Risankizumab was the most frequently reported agent (10/12 studies), while only one study evaluated mirikizumab and another evaluated guselkumab, both exclusively in UC cohorts. Across nine studies reporting on clinical response (n = 516), 64% of patients achieved symptomatic improvement following dose escalation (56% CD; 67% UC). Clinical remission rates varied by agent and cohort but ranged from 31.2% in UC cohorts (n = 359) to 68% in one CD cohort (n = 24). Endoscopic improvement after dose escalation was reported in 3 studies, reaching 16.8% in UC across 2 cohorts (n = 340), and 67% in a small CD cohort on Risankizumab (n = 6). Biomarker outcomes reported in 4 studies showed consistent reductions in CRP and fecal calprotectin, although sample sizes for biomarker analyses were inconsistently reported. No increase in adverse events was associated with dose escalation. In this first systematic review of IL-23 inhibitors dose escalation in IBD, dose escalation was effective and well-tolerated, recapturing clinical response in the majority of patients with inadequate primary or secondary response to standard dosing. These findings support dose escalation as a viable strategy in clinical practice, though prospective studies are needed to define optimal escalation protocols and identify predictors of response.

PMID 43042045
阅读全文 →
PubMedBMC global and public health2026-11-17

Rising rates of young people not in education, employment, or training explained by higher prevalence of self-reported ill health and psychological distress: a 15-year UK study.

Wels Jacques J, P Kelly Dominic D, Smeeth Demelza D, Bridger Staatz Charis C et al.

Rising rates of young people Not in Education, Employment, or Training (NEET) in the United Kingdom (UK) have recently coincided with declining youth physical and mental health but no study has asked whether this reflects a growing proportion of young people with health problems (prevalence) or those with health problems becoming more likely to be NEET (penalty). Using 15 years of Understanding Society data (2009-23), we analysed 15,242 respondents aged 16-24 (66,160 observations). We employed three complementary approaches: descriptive trends, Blinder-Oaxaca-Kitagawa (BO) probit decomposition comparing 2009-2013 and 2019-2023 against a 2014-2018 reference period, and within-person Poisson models with lagged health status. Exposures included self-reported health conditions or disability (SRHD), psychological distress, diagnosed conditions and socio-demographic factors. NEET rates were lowest in 2014-18 (10.5-11.5%) and higher in 2009-13 (12-15%) and 2019-23 (15-16%). Higher prevalence of SRHD, psychological distress, diagnosed depression and multimorbidity explained changes in NEET prevalence across both the 2009-13 to 2014-2018 and 2014-18 to 2019-23 periods. No change in penalty was observed for any health variable across periods, except for an increase in the penalty for SRHD between the 2009-13 to 2014-18 periods. Rising NEET rates among UK youth are driven largely by more young people having physical and psychological ill health. Whilst labour market and education accommodations remain important, reducing NEET rates will require reversing the decline in youth health, not just accommodating it.

PMID 43040542
阅读全文 →
PubMedGigaScience2026-11-17

Machine learning-based proteomics analysis identified 23 protein biomarkers for enhanced risk prediction of myocardial infarction in Chinese and Europeans.

Wright Neil N, Mazidi Mohsen M, Pozarickij Alfred A, Yao Pang P et al.

Advances in proteomics assays enable measurement of thousands of plasma proteins, which could facilitate machine learning-based approaches to enhance risk prediction of disease. We measured plasma levels of >9500 proteins among 4000 Chinese adults (1937 myocardial infarction [MI] cases and 2026 subcohort), using both Olink Explore (2923 proteins) and SomaScan (6597 proteins) platforms. Protein-based risk prediction models were constructed, using conventional and machine learning approaches, with model performance assessed via discrimination (C-statistic), classification (net reclassification index; NRI) and calibration. Protein scores were compared and combined with conventional risk factors and polygenic scores (PGS), and externally validated in 37,187 Europeans (630 MI cases) in UK Biobank. Overall, 451 Olink and 530 SomaScan proteins were significantly associated (5% false discovery rate) with MI risk after adjustment for conventional risk factors. The protein prediction models based on Olink, SomaScan, or both platforms combined, outperformed conventional risk factors and PGS using discrimination, classification and calibration. The protein score using 23 Boruta-selected (Olink/SomaScan: 11/12) proteins yielded a 3.3-fold difference in 10-year cumulative incidence of MI between the top and bottom 20% risk groups (3.6 [95%CI: 3.1-4.1] vs 1.1 [0.9-1.2] per 100), compared with 2.5-fold (2.5 [2.2-2.9] vs 1.0 [0.9-1.2]) and 1.5-fold (1.9 [1.6-2.1] vs 1.3 [1.1-1.4]) differences for conventional and PGS, respectively. Adding this protein score to conventional risk factors increased C-statistics from 0.846 (0.829-0.862) to 0.864 (0.849-0.879), yielding an NRI of 72%. External validation in 37,187 participants in UK Biobank by adding 23 Boruta-selected proteins to conventional risk factors yielded comparable improvement in C-statistics for MI (from 0.710 [0.688-0.731] to 0.733 [0.710-0.756]) and 45% improvement in NRI (NRI 45%). Machine learning identified subsets of proteins for improved MI risk prediction beyond conventional risk factors and PGS, showing the potential for developing small panel proteomics assays to improve disease risk prediction.

PMID 43043107
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多TJ-23